Royal Bank of Canada’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-19,676
| Closed | -$119K | – | 7311 |
|
|
2019
Q4 | $119K | Buy |
19,676
+11,376
| +137% | +$65.8K | ﹤0.01% | 4995 |
|
|
2019
Q3 | $30K | Buy |
8,300
+800
| +11% | +$3.08K | ﹤0.01% | 5339 |
|
|
2019
Q2 | $20K | Sell |
7,500
-5,009
| -40% | -$14.8K | ﹤0.01% | 5732 |
|
|
2019
Q1 | $37K | Buy |
12,509
+10,009
| +400% | +$24.6K | ﹤0.01% | 5341 |
|
|
2018
Q4 | $4K | Sell |
2,500
-3,615
| -59% | -$10.2K | ﹤0.01% | 6286 |
|
|
2018
Q3 | $22K | Buy |
6,115
+5,419
| +779% | +$16.1K | ﹤0.01% | 5635 |
|
|
2018
Q2 | $2K | Buy |
+696
| New | +$2.37K | ﹤0.01% | 6310 |
|
|
2018
Q1 | – | Sell |
-894
| Closed | -$3K | – | 7058 |
|
|
2017
Q4 | $3K | Sell |
894
-10,862
| -92% | -$39.5K | ﹤0.01% | 6232 |
|
|
2017
Q3 | $53K | Buy |
11,756
+10,923
| +1,311% | +$48.5K | ﹤0.01% | 5380 |
|
|
2017
Q2 | $4K | Sell |
833
-4,376
| -84% | -$17.6K | ﹤0.01% | 6149 |
|
|
2017
Q1 | $22K | Sell |
5,209
-40,567
| -89% | -$168K | ﹤0.01% | 5583 |
|
|
2016
Q4 | $189K | Buy |
45,776
+7,262
| +19% | +$38.6K | ﹤0.01% | 4521 |
|
|
2016
Q3 | $312K | Sell |
38,514
-12,867
| -25% | -$109K | ﹤0.01% | 4101 |
|
|
2016
Q2 | $400K | Sell |
51,381
-13,004
| -20% | -$112K | ﹤0.01% | 3881 |
|
|
2016
Q1 | $497K | Buy |
64,385
+11,717
| +22% | +$85.8K | ﹤0.01% | 3649 |
|
|
2015
Q4 | $568K | Buy |
52,668
+46,063
| +697% | +$419K | ﹤0.01% | 3649 |
|
|
2015
Q3 | $46K | Buy |
6,605
+5,555
| +529% | +$45.3K | ﹤0.01% | 5178 |
|
|
2015
Q2 | $9K | Sell |
1,050
-2,865
| -73% | -$27.1K | ﹤0.01% | 6102 |
|
|
2015
Q1 | $38K | Sell |
3,915
-11,685
| -75% | -$146K | ﹤0.01% | 5102 |
|
|
2014
Q4 | $192K | Sell |
15,600
-15,600
| -50% | -$191K | ﹤0.01% | 4378 |
|
|
2014
Q3 | $311K | Buy |
31,200
+29,200
| +1,460% | +$271K | ﹤0.01% | 3880 |
|
|
2014
Q2 | $15K | Sell |
2,000
-21,607
| -92% | -$86.2K | ﹤0.01% | 5297 |
|
|
2014
Q1 | $77K | Sell |
23,607
-5,000
| -17% | -$17.5K | ﹤0.01% | 4671 |
|
|
2013
Q4 | $95K | Sell |
28,607
-11,813
| -29% | -$34.3K | ﹤0.01% | 4615 |
|
|
2013
Q3 | $122K | Buy |
40,420
+33,620
| +494% | +$230K | ﹤0.01% | 4362 |
|
|
2013
Q2 | $56K | Buy |
+6,800
| New | +$51.9K | ﹤0.01% | 4607 |
|
Royal Bank of Canada's ACHN Position: Q1 2020 in Review
Royal Bank of Canada sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 19,676 shares — an estimated $119K sold.
Royal Bank of Canada first reported a position in ACHN in Q2 2013 and held it in 26 quarters. The position peaked at $568K in Q4 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Royal Bank of Canada reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Royal Bank of Canada sold 19,676 Achillion Pharmaceuticals shares in Q1 2020, an estimated $119K.
- Royal Bank of Canada first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 26 quarters.
- Royal Bank of Canada's Achillion Pharmaceuticals position peaked at $568K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Royal Bank of Canada's 13F filing for Q1 2020, filed 15 May 2020.